Literature DB >> 16713745

Do cytokine concentrations in pancreatic juice predict the presence of pancreatic diseases?

Kyung W Noh1, Surakit Pungpapong, Michael B Wallace, Timothy A Woodward, Massimo Raimondo.   

Abstract

BACKGROUND & AIMS: Cytokine concentration in pancreatic juice of patients with pancreatic disease is unknown. Secretin stimulation allows endoscopic collection of pancreatic juice secreted into the duodenum. We aimed to evaluate the cytokine concentrations in pancreatic juice of patients with abdominal pain to discriminate presence from absence of pancreatic disease.
METHODS: From January 2003-December 2004, consecutive patients with abdominal pain compatible with pancreatic origin were enrolled. Patients underwent upper endoscopy. Intravenous secretin (0.2 mug/kg) was given immediately before scope intubation. Pancreatic juice collected from the duodenum was immediately snap-frozen in liquid nitrogen until assays were performed. Pancreatic juice levels of interleukin-8, interleukin-6, intercellular adhesion molecule 1, and transforming growth factor-beta 1 were measured by modified enzyme-linked immunosorbent assays. The final diagnosis was made by the primary gastroenterologist on the basis of medical history; laboratory, endoscopic, and imaging studies; and clinical follow-up. Fisher exact test and Kruskal-Wallis rank sum test were used for statistical analysis.
RESULTS: Of 130 patients screened, 118 met the inclusion criteria. Multivariate analysis revealed that only interleukin-8 was able to discriminate between normal pancreas and chronic pancreatitis (P = .011), pancreatic cancer (P = .044), and the presence of pancreatic diseases (P = .007). Individual cytokine concentrations were not significantly different in chronic pancreatitis compared with pancreatic cancer.
CONCLUSIONS: Cytokine levels can be measured in pancreatic juice obtained from the duodenum without direct cannulation of the pancreatic duct. Interleukin-8 concentration in pancreatic juice can be used to discriminate between normal pancreas and patients with pancreatic disease. This is a relatively simple and noninvasive method to aid in the diagnosis of pancreatic diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16713745     DOI: 10.1016/j.cgh.2006.03.026

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  23 in total

1.  Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Authors:  Geou-Yarh Liou; Heike Döppler; Brian Necela; Brandy Edenfield; Lizhi Zhang; David W Dawson; Peter Storz
Journal:  Cancer Discov       Date:  2014-10-31       Impact factor: 39.397

Review 2.  Classification and diagnosis of chronic pancreatitis.

Authors:  Peter A Banks
Journal:  J Gastroenterol       Date:  2007-01       Impact factor: 7.527

3.  Cytokine profiling of pancreatic fluid using the ePFT collection method in tandem with a multiplexed microarray assay.

Authors:  Joao A Paulo; Linda S Lee; Bechien Wu; Peter A Banks; Hanno Steen; Darwin L Conwell
Journal:  J Immunol Methods       Date:  2011-05-01       Impact factor: 2.303

Review 4.  Nuclear receptors and pathogenesis of pancreatic cancer.

Authors:  Simone Polvani; Mirko Tarocchi; Sara Tempesti; Andrea Galli
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 5.  Endoscopic Pancreas Fluid Collection: Methods and Relevance for Clinical Care and Translational Science.

Authors:  Phil A Hart; Mark Topazian; Massimo Raimondo; Zobeida Cruz-Monserrate; William E Fisher; Gregory B Lesinski; Hanno Steen; Darwin L Conwell
Journal:  Am J Gastroenterol       Date:  2016-08-02       Impact factor: 10.864

6.  The Effect of Pancreatic Juice Collection Time on the Detection of KRAS Mutations.

Authors:  Masaya Suenaga; Beth Dudley; Eve Karloski; Michael Borges; Marcia Irene Canto; Randall E Brand; Michael Goggins
Journal:  Pancreas       Date:  2018-01       Impact factor: 3.327

7.  Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Ajay V Maker; Nora Katabi; Li-Xuan Qin; David S Klimstra; Mark Schattner; Murray F Brennan; William R Jarnagin; Peter J Allen
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

Review 8.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

Review 9.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

10.  Adipokines and cytokines in human pancreatic juice: unraveling the local pancreatic inflammatory milieu.

Authors:  Kathryn M Dalbec; C Max Schmidt; Terence E Wade; Sue Wang; Deborah A Swartz-Basile; Henry A Pitt; Nicholas J Zyromski
Journal:  Dig Dis Sci       Date:  2009-09-16       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.